Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias

INTRODUCTION: Bosutinib is a dual ABL1 and SRC third generation tyrosine kinase inhibitor (TKI) indicated for the treatment of patients with chronic myelogenous leukemia (CML) resistant to or intolerant of other BCR-ABL1 inhibitors. Bosutinib is active against leukemia cells expressing imatinib-resi...

Full description

Saved in:
Bibliographic Details
Published in:Expert Opin Orphan Drugs
Main Authors: Varallo-Rodriguez, Cristina, Freyer, Craig W., Ontiveros, Evelena P., Griffiths, Elizabeth A., Wang, Eunice S, Wetzler, Meir
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6684277/
https://ncbi.nlm.nih.gov/pubmed/31388478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/21678707.2015.1036027
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items